

1 **Title: Highly concentrated trehalose induces transient senescence-associated**  
2 **secretory phenotype in fibroblasts via CDKN1A/p21**

3  
4 **Authors:** Jun Muto<sup>1\*</sup>, Shinji Fukuda<sup>2</sup>, Kenji Watanabe<sup>3</sup>, Xiuju Dai<sup>1</sup>, Teruko Tsuda<sup>1</sup>, Takeshi Kiyoi<sup>4</sup>,  
5 Hideki Mori<sup>1</sup>, Ken Shiraishi<sup>1</sup>, Masamoto Murakami<sup>1</sup>, Shigeki Higashiyama<sup>5, 6</sup>, Yoichi Mizukami<sup>3</sup>,  
6 Koji Sayama<sup>1</sup>

7  
8 **Affiliations:**

9 <sup>1</sup>Department of Dermatology, Ehime University Graduate School of Medicine; Toon, Japan.

10 <sup>2</sup>Department of Biochemistry, School of Dentistry, Aichi Gakuin University; Nagoya, Japan.

11 <sup>3</sup>Institute of Gene Research, Yamaguchi University Science Research Center; Yamaguchi, Japan.

12 <sup>4</sup>Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Japan.

13 <sup>5</sup>Division of Cell Growth and Tumor Regulation, Proteo-Science Center, Ehime University; Toon,  
14 Japan.

15 <sup>6</sup>Department of Molecular and Cellular Biology, Osaka International Cancer Institute; Osaka, Japan.

16 \*Corresponding author. Email: [junmuto@m.ehime-u.ac.jp](mailto:junmuto@m.ehime-u.ac.jp)

17

18

19

20

21

22

23

24

25

26

27

28 **Definitions of abbreviations:**

29 ANGPT2: angiopoietin-2;  $\alpha$ -SMA:  $\alpha$ -smooth muscle actin; AURKA: Aurora kinase A; AURKB:  
30 Aurora kinase B; CDKN1A: cyclin-dependent kinase inhibitor 1A; DPT: dermapontin; EREG:  
31 epiregulin; FGF: fibroblast growth factor; GM-CSF: granulocyte macrophage colony-stimulating  
32 factor; HABP: hyaluronan-binding protein; HIF1 $\alpha$ : hypoxia-inducible factor 1- $\alpha$ ; HA: hyaluronan;  
33 IGF: insulin-like growth factor; IL1RN: IL-1 receptor antagonist; IPA: Ingenuity Pathway Analysis;  
34 LMNB1: Lamin B1; LSE: living skin equivalent; MYBL2: Myb proto-oncogene like 2; OPN:  
35 Osteopontin; PCA: Principal component analysis; PDGFA: platelet-derived growth factor-A; PGF:  
36 placental growth factor; PLK1: Polo-like kinase 1; qPCR: quantitative PCR; RNA-seq: RNA-  
37 sequencing; ROS: reactive oxygen species; SA  $\beta$ -gal: senescence-associated  $\beta$ -galactosidase; SASP:  
38 senescence-associated secretory phenotype; TGF: transforming growth factor; VEGF: vascular  
39 endothelial growth factor.

40

41 **Abstract:** Trehalose is the nonreducing disaccharide of glucose, evolutionarily conserved in  
42 invertebrates, but does not exist in vertebrates. The living skin equivalent (LSE) is an organotypic  
43 coculture containing keratinocytes cultivated on fibroblast-populated dermal substitutes. We  
44 demonstrated that human primary fibroblasts treated with highly concentrated trehalose promote  
45 significantly extensive spread of the epidermal layer of LSE without any deleterious effects. The  
46 RNA-seq analysis data and Ingenuity pathway analysis of the differentially expressed genes of  
47 trehalose-treated 2D and 3D fibroblasts at early time points revealed the involvement of the  
48 CDKN1A pathway, which is necessary for the marked upregulation of growth factors including  
49 DPT. By contrast, the mRNA-seq data of LSEs 2-weeks after air exposure indicated that gene  
50 expression profiles are similar for untreated and trehalose-treated cells in both keratinocytes and  
51 fibroblasts. The trehalose-treated fibroblasts were positive for senescence-associated  $\beta$ -  
52 galactosidase with the significantly downregulated expressions of LMNB1. Finally, we  
53 demonstrated that transplantation of the dermal substitute with trehalose-treated fibroblasts  
54 accelerated wound closure and increased capillary formation significantly in the experimental  
55 mouse wounds *in vivo*. These data indicate that high-concentration trehalose can induce the  
56 beneficial senescence-associated secretory phenotype in fibroblasts via CDKN1A/p21, which may  
57 be therapeutically useful for optimal wound repair.

58

59

60 **Main Text:**

61 **INTRODUCTION**

62 Trehalose ( $\alpha$ -D-glucopyranosyl  $\alpha$ -D-glucopyranoside) is the nonreducing disaccharide of glucose,  
63 evolutionarily conserved in eukaryotes, plants, and invertebrates, but does not exist in vertebrates  
64 (Elbein, 1974). A pivotal method of synthesis that has dramatically reduced the production cost  
65 (Ohtake and Wang, 2011). Trehalose has been demonstrated as multifunctional and was utilized to  
66 stabilize lipids, proteins, enzymes, and tissues (Ohtake and Wang, 2011). The organ preservation  
67 solution, which was named extracellular-type trehalose-containing solution, was demonstrated to be  
68 more effective in preserving lung quality after clinical lung transplantation compared with the  
69 primary solution (Yokomise et al., 1995). Tanaka *et al.* reported that trehalose palliates the  
70 polyglutamine-mediated pathology of Huntington disease in mouse models (Tanaka et al., 2004).  
71 Trehalose inhibits the proliferation of fibroblasts owing to its inhibition of fibroblast transformation  
72 into myofibroblasts (Takeuchi et al., 2010). Additionally, a reduction in insulin/IGF-1-like signaling  
73 extends the life span of fibroblasts through an aging-suppressor function (Honda et al., 2010).

74 Bioengineered cellularized skin substitutes are frequently used in clinical applications as an  
75 alternative grafting technique to autografting and as *in vitro* study models, although most of the  
76 currently available models are epidermal sheets that only repair wounds by inducing keratinocytes  
77 rather than guiding a regeneration process. Multi-layered living skin equivalents (LSEs) containing  
78 bi-layered constructs that model the epidermal layer with the differentiated keratinocytes on the  
79 dermal substitutes cultivated with the fibroblasts had been used to treat skin ulcers of burn injury or  
80 epidermolysis bullosa (Kirsner, 1998). The fibroblasts in the dermal matrix of LSEs drive epidermal  
81 proliferation and differentiation through reciprocal action (Andriani et al., 2003). Numerous  
82 biomedical materials, such as type I collagen, acellular human dermis, collagen-glycosaminoglycan  
83 matrices, human plasma, and fibrin glue have been applied as dermal matrix alternatives.  
84 Nevertheless, an ideal matrix that is beneficial, readily available, and has minimal toxicity is yet to  
85 be discovered (Randall et al., 2018). The effect of trehalose on fibroblasts for LSE development  
86 remains elusive. During the course of the trials, we unexpectedly found beneficial effects of  
87 trehalose for LSE development.

88 Cellular senescence has been reported as a stress response in which cells experience stable cell cycle  
89 arrest following stress-inducing stimuli. The most conventional senescence marker is senescence-  
90 associated  $\beta$ -galactosidase (SA  $\beta$ -gal) activity detected after an increase in lysosomal content (Kurz  
91 et al., 2000). These senescent cells maintain metabolic capabilities and feature a hypersecretory



92 phenotype termed the senescence-associated secretory phenotype (SASP) (Coppe et al., 2010).  
93 Although reports have characterized SASP in various cell types, its detailed composition remains  
94 unclear. The SASP is composed of a collection of proinflammatory cytokines, chemokines, and  
95 growth factors, such as epiregulin (EREG), FGF2, and VEGF (Coppe et al., 2010). The transient  
96 initiation of senescence is beneficial and contributes to the cutaneous wound repair process (Jun and  
97 Lau, 2010). Transient senescence seemed to be restricted in fibroblast-like cells, which produce  
98 platelet-derived growth factor-A (PDGFA)-enriched SASP to facilitate cutaneous wound healing  
99 (Demaria et al., 2014). In contrast, fibroblasts in which senescence is induced by oncogenic RAS  
100 oversecrete more granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-6, but not  
101 EREG or vascular endothelial growth factor (VEGF), than cells in which senescence is induced by  
102 other means such as X-irradiation (Coppe et al., 2010). Basisty *et al.* reported the “SASP Atlas,”  
103 which is a comprehensive proteomic database of soluble proteins originating from multiple  
104 senescence inducers and cell types, as well as other candidate biomarkers of cellular senescence that  
105 include growth/differentiation factor 15 (GDF15), stanniocalcin 1 (STC1), and SLC1A5 (Basisty et  
106 al., 2020). Furthermore, Lamin B1(LMNB1) loss is a robust marker of senescence. There is a decline  
107 in *LMNB1* mRNA levels during senescence due to a decrease in *LMNB1* mRNA stability (Freund  
108 et al., 2012).

109 Cell cycle arrest is another feature of senescent cells that is controlled by activation of p53  
110 antiproliferative function. The most pertinent function of p53 in senescence is the acceleration of  
111 cyclin-dependent kinase inhibitor 1A (*CDKN1A*) transcription (Herranz and Gil, 2018). The  
112 *CDKN1A* gene is a major target of the p53 transcription factor, and its product, p21, is a cyclin-  
113 dependent kinase inhibitor, which induces cell cycle arrest (Bartek and Lukas, 2001). In a p53-  
114 induced senescence model, Akt activation and cooperation between p21 and Akt were mandatory  
115 for cellular senescence phenotype induction (Kim et al., 2017). Polo-like kinase 1 (PLK1) is a key  
116 molecule in the G2/M transition. The induction of *CDKN1A* rapidly decreases cellular levels of the  
117 *PLK1* promoter activity (Zhu et al., 2002). Furthermore, high levels of p21 induce G2 arrest in  
118 normal human fibroblasts (Baus et al., 2003).

119 In this study, we investigated the effect of trehalose on fibroblasts mixed in type 1 collagen gel and  
120 tested whether it could affect LSE construction. We performed RNA-seq of the treated fibroblasts.  
121 Subsequently, the therapeutic potential of trehalose-treated fibroblasts in the dermal substitute as a  
122 biological dressing was investigated via skin grafting onto the full-thickness wounds of  
123 BALB/cAJc1-nu nude mice *in vivo*. These results provide an avenue for the development of a novel  
124 organotypic skin culture system for future therapeutic exploitation.

## 125 RESULTS

### 126 Rapid spread of LSEs containing trehalose in the fibroblast-populated collagen gel

127 LSEs have been used to treat skin defects. However, production of LSEs takes approximately 4  
128 weeks, which makes LSE production impractical for applications in regenerative medicine. To  
129 investigate the beneficial effects of trehalose on fibroblasts, we constructed fibroblast-populated  
130 type I collagen gel with trehalose, upon which normal human keratinocytes were seeded to form  
131 LSEs. The sizes of the LSEs were observed after 2 weeks of airlifting at 37°C (*Figure 1A*). We  
132 evaluated the diameters of LSEs prepared in Transwell-COL with a 24-mm insert in a six-well  
133 culture plate, and the diameters of LSEs prepared with trehalose were significantly larger than those  
134 of LSEs prepared without trehalose after 2 weeks of airlifting (*Figure 1, B and C*). We confirmed  
135 this phenomenon in skin fibroblasts and keratinocytes derived from cells of three other patients 1  
136 week after air exposure (*Figure 1-figure supplement 1, A to C*).

137 Two weeks after airlifting, hematoxylin and eosin staining was used to compare the LSEs containing  
138 trehalose (10 or 100 mg/ml) with the control LSEs. Interestingly, they were morphologically  
139 indistinguishable besides the size of the final products (*Figure 1D*). Next, paraffin-embedded  
140 sections of LSEs were subjected to immunohistochemistry with the Ki67 antibody to assess the  
141 proliferation of fibroblasts. Conversely, fibroblasts in the collagen gel with trehalose showed  
142 increased Ki67 positivity and proliferative capacity (*Figure 1D*). Additionally, we examined elastic  
143 and collagen fibers in the three-dimensional culture system with or without trehalose by Elastica  
144 van Gieson staining. Histological analysis revealed that collagen fiber (stained red) and elastic fiber  
145 (stained black) were morphologically similar among the three groups (*Figure 1-figure supplement*  
146 *2A*). Hyaluronan can be detected histologically by using hyaluronan-binding protein (HABP).  
147 Interestingly, the HABP staining did not reveal differences in hyaluronan (HA) distribution between  
148 the LSEs with or without trehalose (*Figure 1-figure supplement 2B*). Alcian blue staining (pH 2.5)  
149 was used to visualize the formation of sulfated and carboxylated acid mucopolysaccharides and  
150 sialomucins in the LSEs (stained blue), with no significant changes observed between the three  
151 groups (*Figure 1-figure supplement 2C*).  $\alpha$ -Smooth muscle actin ( $\alpha$ -SMA) is used as a marker for  
152 myofibroblasts, which is a subset of activated fibrogenic cells. In the LSEs,  $\alpha$ -SMA-positive cells  
153 were similarly densely lined at the dermal-epidermal junction of the three groups (*Figure 1-figure*  
154 *supplement 2D*). These data demonstrated that trehalose added to the collagen gel significantly  
155 accelerated proliferation of epidermal sheets, which are morphologically and histologically  
156 indistinguishable from vehicle-treated control LSEs.

157 To investigate the novel effect of trehalose further, we prepared larger LSEs using a larger culture  
158 insert (75-mm diameter), with proportionally more fibroblasts and keratinocytes. A rubber ring (8-  
159 mm interior diameter) was covered over the fibroblast-containing gel to stabilize it, and  
160 keratinocytes were seeded in the ring hole. The epidermal layer of LSEs containing trehalose (100  
161 mg/ml) in the gel harvested after 2-week airlifting at 37°C spread markedly, and thus, the  
162 experimental LSEs were substantially larger than the control LSEs under the same conditions  
163 (*Figure 1-figure supplement 3*).

164 To examine the signaling pathways modulated by trehalose treatment in the 3D skin model, we  
165 comprehensively analyzed mRNA expressions in the epidermis and dermis of LSEs cultured in  
166 collagen gel containing trehalose (100 mg/ml) 2-weeks after air exposure. RNA-sequencing (RNA-  
167 seq) analysis revealed that genes significantly modulated by trehalose were undetected at 14 days in  
168 the keratinocytes except for the upregulated bone morphogenic protein 6 (*BMP6*) gene and the  
169 downregulated *LINC00302* gene (*Figure 1E*). In the fibroblasts, the gene expressions by trehalose  
170 resembled those in the vehicle cells, and only four genes (*SCARNA22*, *PTCHD4*, *RP11-137H2.6*,  
171 and *NPR3*) were significantly regulated by the addition of trehalose (*Figure 1E*). Principal  
172 component analysis (PCA) provided no major difference in the gene expression of the keratinocytes  
173 and fibroblasts by trehalose treatment (*Figure 1F*). In addition, the factor loadings of genes in PC1  
174 and PC2 showed no effect on trehalose treatment. Our observations indicated that gene expression  
175 profiles in a long culture of 3D gels are similar for untreated and trehalose-treated cells in both  
176 keratinocytes and fibroblasts. Next, we examined whether fibroblast pretreated with trehalose before  
177 seeding in the collagen gel achieved increased proliferation of the epidermal layer of the 3D culture  
178 model (*Figure 1G*). Interestingly, LSEs with fibroblast pretreated with trehalose (30 or 100 mg/ml)  
179 accelerated the spread of the epidermal layer compared with the control LSEs (*Figure 1H*). These  
180 observations indicated that trehalose pretreatment on the fibroblast monolayer before seeding in the  
181 gel can induce significantly accelerated proliferation of the keratinocyte layer of LSE.

## 182 **Whole transcriptome analysis in trehalose-treated 2D and 3D fibroblasts**

183 Gene expression profiles of both keratinocytes and fibroblasts in a long culture of 3D gels treated  
184 with trehalose were similar to those of the untreated cells. Thus, we comprehensively examined the  
185 transient gene expressions in the trehalose-pretreated fibroblasts using RNA-seq. Trehalose (100  
186 mg/ml) treatment for 24 h induced upregulation of 1,256 genes ( $FC > 2.0$ ,  $q < 0.01$ ) and  
187 downregulation of 484 genes ( $FC < 0.5$ ,  $q < 0.01$ ) in the 2D culture compared with those of untreated  
188 cells. In the 3D culture, 267 genes or 332 genes were upregulated ( $FC > 2$ ,  $q < 0.01$ ) or

189 downregulated ( $FC < 0.5$ ,  $q < 0.01$ ), respectively, by 72-h trehalose treatment (*Figure 2-figure*  
190 *supplement 1, A and D*). The gene expression profiles of the fibroblasts in 2D and 3D cultures were  
191 clearly separated by PC2 in PCA from those of untreated cells, indicating that trehalose affects  
192 cellular function through gene expressions (*Figure 2-figure supplement 1, B and E*). We plotted the  
193 factor loadings of the genes in PC1 and PC2 to observe the gene expressions involved in PC2  
194 separation. As the positively contributing genes, growth factors, such as dermapontin (*DPT*), *EREG*,  
195 *FGF2*, and angiopoietin-2 (*ANGPT2*), were observed in both 2D and 3D cultures in addition to a  
196 cell cycle inhibitor, *CDKN1A* (*Figure 2-figure supplement 1, C and F*). The cell cycle-related genes,  
197 Aurora kinase A (*AURKA*), *PLK1*, and Myb proto-oncogene like 2 (*MYBL2*) negatively participated  
198 in the PC2 separation of 2D and 3D cultures treated with trehalose (*Figure 2-figure supplement 1,*  
199 *C and F*). Treatment with highly concentrated trehalose in the fibroblast cells suggests strict  
200 regulation of the cell cycle despite the release of various growth factors.

201 To elucidate the signaling pathways activated in highly concentrated trehalose-treated fibroblasts,  
202 we analyzed the interaction network with Ingenuity Pathway Analysis (IPA) using the information  
203 collected from databases on protein interactions. In the presence of trehalose, 131 genes were  
204 downregulated in common in 2D and 3D culture, and the expression patterns were shown on the  
205 heatmap, which included cell cycle-related genes such as Aurora kinase B (*AURKB*), *PLK1*, and  
206 Anillin actin-binding protein (*ANLN*) (*Figure 2, A and B*). The downregulated genes revealed the  
207 reduction of kinetochore metaphase signaling, G2/M DNA damage, and the cell cycle checkpoint  
208 in the canonical pathways (*Figure 2C*). With respect to upstream factors, asparaginase, a drug for  
209 acute lymphoblastic leukemia, was detected in the upstream analysis and is able to arrest the cell  
210 cycle. ZBTB17 is a transcriptional negative regulator in the cell cycle (*Figure 2D*). *CDKN1A* was  
211 also detected as an upstream factor based on the significant decrease of *PLK1*, *CDK1*, *CCNA2*, and  
212 *CDC25A* after trehalose treatment (*Figure 2E*). The inhibition of *CDK1* and *CCNA2* was suggested  
213 to partially induce the reduction of *MYBL2*. The 127 upregulated genes were observed in both 2D  
214 and 3D cultures (*Figure 2, F and G*), and contained *CDKN1A* was detected as an upstream factor of  
215 downregulated genes (*Figure 2D*). The pathway analysis using upregulated genes revealed the p53  
216 signaling pathway involving in cell cycle arrest (*Figure 2H*). Inhibition of *AURK* and *ANLN* were  
217 detected as upstream factors in the upregulated genes and were also observed in downregulated  
218 genes in the presence of trehalose (*Figure 2, I and J*). We integrated the upregulated genes into the  
219 downregulated genes and analyzed the signaling pathways because the pathways detected by the  
220 upregulated genes were closely related to the pathways of the downregulated genes (*Figure 3A*).  
221 The graphical summary connected the network analysis to the cellular functions and showed that

222 the senescence cells were activated by p53 and CDKN1A related to the cell cycle regulation and  
223 mitosis arrest (*Figure 3B*). In the network analysis, activation of DPT and VEGF were suggested to  
224 be induced by the Notch and Caspase (*Figure 3-figure supplement 1, A and B*). The mRNA  
225 expressions of genes involving cellular senescence, *CDKN1A*, and *LMNB1* were confirmed by  
226 quantitative PCR (qPCR) in 2D fibroblasts (*Figure 4A*). Western blot analysis revealed that  
227 trehalose treatment increased p21 expression and decreased lamin B in a dose-dependent manner  
228 (*Figure 4B*). The dose-dependently increased expression of p21 in the nuclei after trehalose  
229 treatment was confirmed using fluorescence microscopy (*Figure 4C* and *Figure 4-figure supplement*  
230 *1*). Furthermore, mRNA expressions of genes involved in cellular functions such as cell cycle  
231 regulation, *AURKA*, *AURKB*, *PLK1*, and *MYBL2* were confirmed by qPCR in 2D fibroblasts (*Figure*  
232 *4D*) and 3D fibroblasts (*Figure 4E*). Additionally, we also confirmed these effects of trehalose with  
233 the fibroblasts derived from three other patients. These findings suggested that trehalose possesses  
234 the ability to temporarily upregulate *CDKN1A* and downregulate *AURKA*, *AURKB*, *UBE2*, *PLK1*,  
235 *MYBL2*, and *LMNB1*, thus leading to cell cycle arrest and transient senescence of the fibroblasts.

### 236 **Fibroblasts in G2/M interphase and Erk1/2- and Akt-activated senescence**

237 To further explore the effects of highly concentrated trehalose, we studied morphological alterations  
238 of fibroblasts after trehalose treatment. Phase contrast microscopy revealed dose-dependent  
239 morphological differences between fibroblasts cultured with or without trehalose. We observed that  
240 the shape of cells cultured with trehalose remained polygonal/expanded, although the control cells  
241 became fusiform/elongated (*Figure 5A* and *Video 1-3*). In *Figure 5A* and *the video 1-3*, we  
242 demonstrate that trehalose inhibited the population growth of monolayer fibroblast cells. Further, to  
243 clarify trehalose-induced cell proliferation inhibition, we examined cell viability via CCK8 assay.  
244 Trehalose slightly inhibited cellular proliferation of the fibroblasts (*Figure 5-figure supplement 1*).  
245 Importantly, instead of trehalose, we observed that a high-concentration sucrose (100 mg/ml) in the  
246 medium inhibited cell proliferation and induced cell death in human dermal fibroblasts (*Figure 5-*  
247 *figure supplement 1* and *Video 4*). Fibroblasts were characterized for a potential senescent  
248 phenotype via SA- $\beta$ GAL staining, which revealed that more trehalose-treated fibroblasts than  
249 vehicle-treated fibroblasts were SA- $\beta$ GAL positive (*Figure 5B*). These findings indicate that high-  
250 concentration trehalose induces the cytostatic effect and senescence.

251 Next, fibroblasts treated with or without trehalose for 24 h were further investigated by Western  
252 blotting. High-concentration trehalose activated ERK1/2 and AKT (*Figure 5C*). To further analyze  
253 the effect of trehalose on cell cycle progression, fibroblasts treated with or without trehalose were



254 analyzed by flow cytometry after propidium iodide staining. Of the cells treated with trehalose (100  
255 mg/ml), 30% were arrested in the G2/M interface, whereas 20% of the cells treated without trehalose  
256 were arrested in the G2/M interface (*Figure 5D*). In addition, human dermal fibroblasts in the LSEs  
257 were stained with propidium iodide 7 days after air exposure, and the percentage of G2/M cells was  
258 measured by flow cytometry. Interestingly, 10% of cells treated with trehalose (100 mg/ml) were  
259 arrested in the G2/M interface, whereas almost none of the cells treated without trehalose  
260 accumulated in the G2/M interface (*Figure 5E*). Furthermore, there was significantly higher  
261 superoxide radical generation in those fibroblasts treated with trehalose (*Figure 5-figure supplement*  
262 *2*). Therefore, we conclude that trehalose triggers two antagonistic cell cycle regulatory pathways  
263 in fibroblasts: the classical mitogenic ERK and AKT pathway and a novel G2/M cell cycle arrest  
264 pathway with induction of p21.

### 265 **Upregulation of wound healing-related genes in trehalose-treated fibroblasts**

266 Senescent cells exhibit a hypersecretory phenotype, which has been referred to as the SASP (Coppe  
267 et al., 2010). The SASP comprises a collection of growth factors (Coppe et al., 2010, Wilkinson and  
268 Hardman, 2020). The beneficial and transient initiation of senescence could contribute significantly  
269 to a cutaneous wound healing process (Jun and Lau, 2010). Next, we aimed to elucidate the  
270 characteristics of these high-concentration trehalose-induced SASPs in human fibroblasts. RNA-seq  
271 analysis data and the IPA of the differentially expressed genes revealed significant upregulation of  
272 10 wound healing-related genes—*EREG*, *ARG2*, *CCL2*, *IL1RN*, *PGF*, *SPPI*, *VEGFA*, *FGF2*,  
273 *ANGPT2*, and *DPT*. Then, to confirm RNA-seq findings, qPCR mRNA expression analysis of the  
274 wound healing-related genes was performed, which revealed a significant increase in fibroblasts  
275 treated with trehalose (30 or 100 mg/ml) for 24 h compared with vehicle- or HA-treated control  
276 fibroblast (*Figure 6A*). We confirmed these effects of trehalose using the fibroblasts derived from  
277 three other patients. DPT has a vital role in promoting keratinocyte migration during re-  
278 epithelialization in wound healing (Krishnaswamy and Korrapati, 2014). DPT secretion in the  
279 medium and DPT expression in the fibroblasts were assessed by ELISA and Western blotting,  
280 respectively. We found a significant increase in DPT protein secretion in the cultured medium 48 h  
281 after trehalose treatment compared with that of the vehicle-treated control fibroblasts by ELISA  
282 (*Figure 6B*). Interestingly, results from western blotting demonstrated trehalose treatment increased  
283 the remarkable DPT protein expression in cell lysate after 48 h (*Figure 6C*). Consistent with these  
284 findings, qPCR mRNA expression analysis of *DPT* in the 3D fibroblasts, which were added in the  
285 collagen gel with trehalose (100 mg/ml) for 72 h, revealed a significant increase compared with that  
286 of the vehicle-treated fibroblasts (*Figure 6D*). Furthermore, RNA-seq analysis of the 3D fibroblasts

287 revealed 267 upregulated genes in the trehalose-treated fibroblasts compared with those of the  
288 vehicle-treated control fibroblasts, including significant upregulation of nine wound healing-related  
289 genes—*EREG*, *ARG2*, *CCL2*, *IL1RN*, *PGF*, *SPPI*, *VEGFA*, *FGF2*, and *ANGPT2*. Then, to confirm  
290 RNA-seq findings, qPCR mRNA expression analysis of these wound healing-related genes was  
291 performed; this revealed a significant increase in the 3D fibroblasts that were added in the collagen  
292 gel with trehalose (100 mg/ml) for 72 h compared with that of the control fibroblasts (*Figure 6D*).

### 293 **CDKN1A is involved in the upregulation of SASP factor genes**

294 Next, we investigated the involvement of CDKN1A in trehalose-induced SASP in 2D fibroblasts.  
295 CDKN1A siRNA transfection significantly suppressed its mRNA levels, confirming successful  
296 CDKN1A knockdown (*Figure 7*). CDKN1A knockdown significantly suppressed the upregulation  
297 of *DPT*, *ANGPT2*, *VEGFA*, *EREG*, *FGF2* mRNA levels after trehalose treatment (*Figure 7*),  
298 suggesting the critical role of CDKN1A in trehalose-induced SASP in fibroblasts.

### 299 **Effect of high-concentration trehalose on the expression of non-inflammatory SASP factor** 300 **genes**

301 The SASP is closely associated with positive and negative outcomes depending on cell types and  
302 contexts. Senescent cells also generate proinflammatory molecules and matrix metalloproteinases.  
303 Next, we investigated whether trehalose-induced cellular senescence in monolayer and organotypic  
304 cultures of human fibroblasts would lead to similarly dramatic changes in senescence factors  
305 induced by other stressors. Surprisingly, analysis of RNA-seq data revealed that SASP factor genes  
306 related to inflammation, such as *IL-6*, *IL-8*, and *IL-1B*, were not elevated, whereas several genes  
307 associated with senescence, such as *GDF15*, *MMP3*, and *TNFRSF10C*, were upregulated (*Table 1*).  
308 Overall, our data support the hypothesis that trehalose elicits the non-inflammatory SASP.

### 309 **Dermal substitute with high-concentration trehalose-treated fibroblasts enhances wound** 310 **closure and capillary formation**

311 Since trehalose treatment upregulated wound healing-related genes in the 3D culture system, 6 mm  
312 × 6 mm full skin thickness excisional wounds were made on the dorsum of nude mice (BALB/cAJcl-  
313 nu). The dermal substitutes composed of collagen and fibroblasts with or without trehalose (100  
314 mg/ml) were further transplanted to test whether trehalose-treated fibroblasts in the dermal substitute  
315 accelerate wound closure *in vivo*. In the macromorphological analysis, we detected a significant  
316 tendency toward promoted healing in the high-concentration trehalose-treated group compared with  
317 the control group (*Figure 8, A and B*). Induction of neoangiogenesis was observed 7 days after

318 transplantation of the dermal substitute with high-concentration trehalose (*Figure 8C*). Furthermore,  
319 statistical analysis demonstrated a significant difference in the narrower wound opening of the  
320 trehalose-treated dermal substitute group as detected histologically by hematoxylin and eosin  
321 staining 7 days after transplantation (*Figure 8, D and E*). We also stained the tissue with antibodies  
322 against CD31. Compared with that in the vehicle-treated group, a significantly greater number of  
323 vessels in the wounds transplanted with the trehalose-treated dermal substitute stained positive for  
324 CD31 (*Figure 8, F and G*). Therefore, the dermal substitute with trehalose-treated fibroblasts  
325 accelerated wound healing by promoting capillary formation *in vivo*.

326

## 327 **DISCUSSION**

328 The challenge to engineer cultured epidermal autografts for the life-saving treatment of patients with  
329 extensive, full-thickness burns was accomplished using the method of keratinocyte-cultivation  
330 described by Rheinwald and Green (O'Connor et al., 1981, Rheinwald and Green, 1975). However,  
331 their method requires the use of a feeder layer of lethally irradiated mouse 3T3 cells and serum.  
332 Therefore, the regulatory issues have necessitated the use of xenotransplantation and development  
333 of cultivation technology. Moreover, epidermal grafts without the dermis are less resistant to trauma  
334 and more prone to post-transplantation contracture, leading to the poor functional and cosmetic  
335 outcomes. An autograft full-thickness LSE can not be used to treat patients with burns due to the  
336 time required for preparation, despite the advances in the methods for rapid *ex vivo* expansion. In  
337 this report, we demonstrated a breakthrough for the new techniques for the rapid development of  
338 LSE using the effect of highly concentrated trehalose added to collagen gel, even as a pretreatment,  
339 which induces the transient beneficial SASP in human fibroblasts via CDKN1A/p21 and modulates  
340 the capacity to accelerate the proliferation of keratinocytes in the epidermal layer of LSE.  
341 Furthermore, the trehalose-treated skin equivalents promoted wound repair with an angiogenic  
342 effect *in vivo* (*Figure 9*).

343 These observations elucidate important physiologic roles for fibroblasts in the construction of LSE  
344 *in vitro* and in wound repair *in vivo*. Our 3D culture system confirmed the role of trehalose-treated  
345 fibroblasts in keratinocyte proliferation. Somewhat surprisingly, we observed the upregulation of  
346 growth factors such as DPT, FGF2, EREG, VEGF, and ANGPT2 as growth factors in the highly  
347 concentrated trehalose-induced SASP. Importantly, we discovered that this effect of trehalose was  
348 transient and occurred only at an early time point, because RNA-seq analysis revealed similar gene  
349 expression profiles for trehalose-treated and the vehicle-treated keratinocytes and fibroblasts in the



350 final LSE preparations. Furthermore, we found that trehalose-induced SASP was relatively non-  
351 inflammatory compared with other stress-induced SASPs. Therefore, trehalose-induced transient  
352 non-inflammatory SASP of human fibroblasts is a novel approach for accelerating keratinocyte  
353 proliferation in LSE and wound healing *in vivo*. We propose this trehalose-induced SASP to be  
354 named “trehalose-induced senescence-associated secretory phenotype (TISASP).” These composite  
355 grafts associating autologous keratinocytes with fibroblasts may have a major impact on chronic  
356 wound therapy. We observed that the addition of sucrose of the same concentration (100 mg/ml) in  
357 the medium induced cell death in human dermal fibroblasts, suggesting that TISASP is not due to  
358 the stress of the disaccharide-induced osmotic pressure.

359 The use of RNA-seq technology enables an unbiased, sensitive method for investigating the  
360 transcriptome of LSEs, 3D fibroblasts, and the 2D monolayer under trehalose treatment. We  
361 identified significantly and differentially expressed genes overlapping between the two data sets for  
362 2D and 3D fibroblasts. RNA-seq analysis data and the IPA of the differentially expressed genes  
363 revealed a potential key role for the CDKN1A pathway for transient G2 arrest based on the discovery  
364 of the upregulation of other growth factors including DPT. The *CDKN1A* gene represents a major  
365 target of the p53 activity, and its product, p21, is the major regulator of the cellular stress response  
366 (Warfel and El-Deiry, 2013). The capacity of p21 for cell cycle arrest depends upon its nuclear  
367 localization (Wu et al., 2011). Our immunocytochemistry results revealed that p21 levels increased  
368 mainly in the nucleus after trehalose treatment. Additionally, the RNA-seq data revealed inhibition  
369 of AURKA and AURKB in the fibroblasts treated with trehalose. The Aurora kinases, including  
370 AURKA and AURKB are highly conserved serine/threonine kinases essential for the control of  
371 mitosis. AURKB indirectly represses the expression of CDKN1A at the transcriptional level  
372 (Trakala et al., 2013). Thus, downregulation of AURKB leads to the induction of p21. Treatment of  
373 cultured multiple myeloma cells with MLN8237, which is a small-molecule and Aurora-A kinase  
374 inhibitor that inhibits Aurora-A gene expression by siRNA, results in G2/M arrest and senescence  
375 *in vitro* (Dutta-Simmons et al., 2009). P21 inhibits AURKA by regulating E2F3 (Wu et al., 2012).  
376 Hence, under the stress of high-concentration trehalose, induced transcription of *CDKN1A* inhibited  
377 AURKA, which led to the G2/M blockade (CDK1-induced mitotic entry). Furthermore, upstream  
378 analysis of RNA-seq data revealed the involvement of ZBTB17, which binds to the *AURKA*  
379 promoter and is assumed to be associated with transcriptional factors that induce *AURKA*  
380 downregulation following topoisomerase I inhibition (Courapied et al., 2010).

381 DeBosch *et al.* reported that activity of glucose transporters at the plasma membrane (SLC2A1:  
382 GLUT1, SLC2A2: GLUT2, SLC2A3: GLUT3, SLC2A4: GLUT4, and SLC2A8: GLUT8), which

383 are expressed in fibroblasts (Longo et al., 1990), is inhibited by 100 mM trehalose (DeBosch et al.,  
384 2016). We treated the fibroblasts with 29.2 (10 mg/ml) to 292 mM (100 mg/ml) trehalose and  
385 observed a dose-dependent effect in our system. Upon glucose restriction in the medium (4.4 mM),  
386 yeast cells underwent transient cell cycle arrest at the G2 phase, which is dependent on the Wee1  
387 tyrosine kinase (Masuda et al., 2016). We identified a significant decrease of *WEE1* mRNA levels  
388 in trehalose-treated 2D and 3D fibroblasts compared with that of the control in our RNA-seq data.  
389 Therefore, trehalose-mediated inhibition of glucose absorption in human dermal fibroblasts might  
390 lead to transient Wee1-independent G2 cell cycle arrest in our system. We also identified increased  
391 mRNA levels of *HIF1A* after trehalose treatment in the cultured monolayer and 3D fibroblasts.  
392 Interestingly, the levels of reactive oxygen species (ROS) in both the mitochondria and the cytosol  
393 increased upon glucose withdrawal, although reduced to the background level upon glucose re-  
394 feeding in human newborn foreskin fibroblasts (Song and Hwang, 2018). There was significantly  
395 higher superoxide radical generation in those fibroblasts treated with trehalose (*Figure 5-figure*  
396 *supplement 2*). The growing body of evidence suggests that ROS induces hypoxia-inducible factor  
397 1- $\alpha$  (HIF1 $\alpha$ ) via MAPK, ERK, and PI3K/AKT pathways (Movafagh et al., 2015). HIF1 $\alpha$  negatively  
398 regulates *AURKA* in breast cancer cell lines under hypoxic conditions (Fanale et al., 2013) and is  
399 involved in *CDKN1A* transcription in murine embryonic fibroblasts (Goda et al., 2003). Hence,  
400 elevated ROS levels after glucose transport inhibition in trehalose-treated fibroblasts induced HIF1 $\alpha$   
401 and could be involved in the subsequent transcription of *CDKN1A*, thus leading to a G2/M blockade  
402 in our system.

403 The role of *CDKN1A* is likely confined to the induction of senescence and cells can resume cycling  
404 upon resolution of stress (Childs et al., 2015). In embryonic development, *CDKN1A* induction leads  
405 to SASP factor expressions, like FGFs, which stimulate cell proliferation and tissue formation (Da  
406 Silva-Alvarez et al., 2019). Importantly, we found highly concentrated trehalose can markedly  
407 increase *CDKN1A*/p21 expression, which is required for a striking upregulation of FGF2 and other  
408 growth factors. Demaria *et al.* analyzed p16<sup>INK4a</sup>/*CDKN1A* double knockout mice, and found that  
409 the wound healing of knockout mice was impaired compared with their wild-type controls, thus  
410 indicating that the presence of senescent cells facilitates skin wound healing, and their absence  
411 significantly suppresses wound closure (Demaria et al., 2014). Thus, transient senescence is critical  
412 for effective cutaneous wound healing. We hypothesize that trehalose treatment can induce a  
413 transient and beneficial senescent phenotype of the human fibroblasts via *CDKN1A*/p21 for optimal  
414 wound healing.

415 Previous studies demonstrated that epidermal growth factor (EGF) family members—transforming  
416 growth factor (TGF)- $\alpha$ , heparin-binding (HB)-EGF, and EREG—act as autocrine growth factors for  
417 normal human keratinocytes (Shirakata, 2010). We also observed dramatic upregulation of *EREG*  
418 after trehalose treatment. EREG is upregulated in the psoriatic epidermis and was initially purified  
419 from the mouse NIH-3T3 (Shirakata, 2010). We also demonstrated that trehalose treatment induced  
420 a marked and significant increase of mRNA and protein levels of DPT, which is a 22-kDa matrix  
421 protein for the interaction with TGF $\beta$ 1, fibronectin, and decorin. DPT dose-dependently promotes  
422 keratinocyte migration in wound repair (Krishnaswamy and Korrapati, 2014). Furthermore,  
423 trehalose attenuates protein aggregation and maintains polypeptide chains in a partially folded state  
424 for the refolding by cellular chaperones (Singer and Lindquist, 1998). Therefore, we speculate that  
425 trehalose plays a role in inducing the secretion of growth factors from fibroblasts and facilitates the  
426 functions of these overexpressed growth factors as chaperones for keratinocyte proliferation on  
427 collagen gels.

428 Although CDKN1A is a vital senescence marker, it is induced during transient cell cycle arrest, thus  
429 must be used in combination with other markers (Herranz and Gil, 2018). A recently emerging  
430 candidate marker that seems to play a role in attenuating senescence is MYBL2, which is a  
431 transcription factor of the MYB family (Musa et al., 2017). The p53–p21 pathway suppresses  
432 MYBL2 expression as a stress response (Fischer et al., 2016). Our RNA-seq results demonstrated  
433 that downregulation of *MYBL2* and target genes transactivated by MYBL2, such as *AURKA*, *CCNA2*,  
434 *CCNB1*, *CDK1*, *PLK1*, and *TOP2A*, are present in human fibroblasts following trehalose treatment,  
435 which indicates that MYBL2 may participate in the senescence phenotype of human fibroblasts after  
436 trehalose treatment. Furthermore, reduced *LMNB1* mRNA expression strongly predicts the  
437 senescence phenotype. *LMNB1* expression decreased in human fibroblasts after trehalose treatment.  
438 Thus, *LMNB1* can be a marker for trehalose-induced senescence.

439 Pertinent roles for transient senescence in tissue injury have been identified during wound repair:  
440 PDGFA-enriched SASP (Demaria et al., 2014). SASP factors include CCL2, which is a chemokine  
441 required for the chemotaxis of macrophages and monocytes during angiogenesis in wound repair.  
442 Recently, Whelan *et al.* demonstrated a novel role of mesenchymal stromal cell-derived CCL2 in  
443 accelerated wound closure (Whelan et al., 2020). In addition, the absence of the IL-1 receptor  
444 antagonist (IL1RN) impaired wound healing along with aberrant NF- $\kappa$ B activation and reciprocal  
445 suppression of the TGF- $\beta$  pathway (Ishida et al., 2006). Placental growth factor (PGF) encodes a  
446 growth factor that is homologous to the vascular endothelial growth factor and is a potent  
447 angiogenic/permeability factor during wound repair (Failla et al., 2000). Osteopontin (OPN) is a

448 glycoprotein that is encoded by secreted phosphoprotein 1 gene (*SPPI*), and analysis of *OPN* null  
449 mutant mice indicated the *in vivo* role of OPN in structural remodeling and resolution of dermal  
450 wounds (Liaw et al., 1998). Angiopoietin 2 encoded by the *ANGPT2* gene acts as a Tie-2 antagonist  
451 (Maisonpierre et al., 1997), thus increasing sensitivity to other proangiogenic factors such as VEGF  
452 (Holash et al., 1999). We demonstrated significant upregulation of these wound healing-related  
453 genes, such as *EREG*, *CCL2*, *IL1RN*, *PGF*, *SPPI*, *VEGFA*, *DPT*, *FGF2*, *ARG2*, and *ANGPT2*, using  
454 RNA-seq and qPCR mRNA expression analysis in trehalose-treated 2D and 3D fibroblasts.  
455 Furthermore, we found that transplantation of a dermal substitute prepared with collagen gel and  
456 fibroblasts treated with trehalose promoted wound healing and capillary formation *in vivo* compared  
457 with wound recovery of the vehicle-treated control. Considered together, trehalose-induced  
458 angiopoietin 2 may act in concert with these SASP factors, such as VEGFA, to stimulate  
459 angiogenesis in the wounds. Although the results are limited to the murine model, we provide  
460 evidence that induction of the transient non-inflammatory senescence-like phenotype by trehalose  
461 in fibroblasts is beneficial for healing skin wounds. In a p53-induced senescence model, cooperation  
462 between p21 and Akt was required for inducing the cellular senescence phenotype and cell cycle  
463 arrest (Kim et al., 2017). Interestingly, we here show that high-concentration trehalose activates  
464 ERK1/2 and AKT in human fibroblasts. By contrast, Wu *et al.* reported intraperitoneally-injected  
465 trehalose promotes the survival of rat skin flaps and angiogenesis by autophagy enhancement due  
466 to inhibition of Akt (Wu et al., 2019). Thus, high-concentration trehalose's mechanism of action is  
467 different from that previously known. Moreover, PGF and VEGFA accelerate diabetic wound  
468 healing, so these gene transfers to diabetic wounds have received increasing attention (Cianfarani et  
469 al., 2006, Sun et al., 2018). Topical application of CCL2 can accelerate cutaneous wound healing in  
470 mice with diabetes by promoting neovascularization (Ishida et al., 2019). Therefore, future  
471 senescence-targeted therapies with trehalose should be reserved for the treatment of chronic wounds  
472 of human diabetic patients.

473 In conclusion, this study demonstrated that highly concentrated trehalose induces transient SASP in  
474 fibroblasts, and revealed that trehalose-induced cell cycle arrest and growth factor secretion via  
475 CDKN1A/p21 are beneficial for keratinocyte proliferation in LSE construction *in vitro* and capillary  
476 formation and wound closure in the repair process *in vivo*. These data suggest a new therapeutic  
477 approach for altering wound responses by applying trehalose-treated fibroblasts for accelerating  
478 wound repair. This could provide the foundation of a new therapy to treat not only genodermatoses  
479 such as epidermolysis bullosa but also chronic diabetic and venous ulcers. Therefore, we believe

480 these findings should promote future studies on the effect of trehalose in modulating fibroblast  
481 functions for LSE construction and subsequent wound therapy.

482

## 483 **MATERIALS AND METHODS**

### 484 **Chemicals and reagents**

485 Trehalose (containing >98.0% trehalose dihydrate, Hayashibara, Okayama, Japan), oligo-  
486 hyaluronan (hyaluronan oligosaccharide 4mer, CSR-11006, Cosmo Bio, Tokyo, Japan), and biotin-  
487 labeled hyaluronic acid-binding protein (HKD, Sapporo, Japan) were purchased.

### 488 **Cell culture**

489 Normal human epidermal keratinocytes were isolated from normal human skin and cultured under  
490 serum-free conditions, following a previously described method (Shirakata et al., 2003, Shirakata et  
491 al., 2004). The cells were used for LSE cultures in their fourth passage. Fibroblasts were isolated  
492 from normal human skin and cultured in Dulbecco's modified Eagle medium (DMEM) (Thermo  
493 Fisher Scientific) supplemented with 10% fetal calf serum, and fifth-passage cells were used to  
494 construct the LSEs. All procedures that involved human subjects received prior approval from the  
495 Ethics Committee of Ehime University School of Medicine, Toon, Ehime, Japan, and all subjects  
496 provided written informed consent.

### 497 **Preparation of cultured skin equivalents with or without trehalose**

498 The method used for LSE preparation was described previously (Yang et al., 2005). Briefly, a  
499 collagen gel was prepared by mixing six volumes of ice-cold porcine collagen type I solution (Nitta  
500 Gelatin, Osaka, Japan) with one volume of  $8 \times$  DMEM, 10 volumes of  $1 \times$  DMEM supplemented  
501 with 20% FBS, and one volume of 0.1 N NaOH, of which 1 ml was added to each culture insert  
502 (Transwell, 3- $\mu$ m membrane pore, Corning, Corning, NY) in a six-well culture plate (Corning).  
503 Following polymerization of the gel in the inserts at 37°C, two volumes of fibroblast suspension  
504 solution  $5 \times 10^5$  cells/ml in  $1 \times$  DMEM supplemented with 10% FBS were added to eight volumes  
505 of the collagen solution (thus, the final collagen concentration was 0.8 mg/ml). Then, 3.5 ml of the  
506 fibroblast-containing collagen solution was applied to each insert. When the fibroblast-containing  
507 gel polymerized, DMEM supplemented with 10% FBS and ascorbic acid (final concentration 50  
508 ng/ml) was added with or without trehalose (in three concentrations: 10, 30, and 100 mg/ml). The  
509 gel was submerged in culture for 5 days until the fibroblasts contracted the gel.

510 A larger LSE was constructed following the same method as previously described except using a  
511 larger culture insert (Transwell, 75-mm diameter, 3- $\mu$ m membrane pore, Corning), thus utilizing  
512 proportionally more fibroblasts. A rubber ring (8-mm interior diameter) was covered over the  
513 fibroblast-containing gel to stabilize it within the large-scale LSE. In the hole of the ring,  $6 \times 10^5$   
514 keratinocytes in 30  $\mu$ l MCDB 153 type II were seeded. The keratinocytes were submerged in culture  
515 for 2 days. When the keratinocytes reached confluence, the LSE was lifted to the air-liquid interface  
516 and a cornification medium (a 1:1 mixture of Ham's F-12 and DMEM supplemented with 2% FBS  
517 and other supplements, as described previously (Yang et al., 2005)) was added. The medium was  
518 changed every other day.

519 To construct the conventional LSE, keratinocytes were seeded onto the contracted gel and then  
520 submerged and airlifted as described above, except without the ring. The seeding cell density was  
521 adjusted using rubber rings. Both LSE types were harvested 7 or 14 days after airlifting. For  
522 hematoxylin and eosin staining, the LSE was fixed in 10% formalin and embedded in paraffin. For  
523 immunohistochemical staining, the LSE was snap frozen in an OCT compound. We performed more  
524 than five experiments and obtained similar results. A representative experiment depicted in the  
525 Figure 1. In comparative studies, keratinocytes and fibroblasts from the same donor were used.

### 526 **Transplanting cultured 3D dermal sheets**

527 The animal grafting protocol was approved by the Ethics Committee of Ehime University School of  
528 Medicine. Ten-week-old female BALB/cAJc1-nu nude mice (CLEA Japan, Tokyo, Japan) were  
529 anesthetized by isoflurane inhalation. Full-thickness wounds were created on the skin of the backs  
530 of each mouse using a 6-mm skin biopsy punch. The fibroblast-containing collagen gels were  
531 prepared with vehicle or trehalose (100 mg/ml) and submerged in culture for 5 days, and the dermal  
532 substitutes (1 day after airlift) were grafted onto the wounds, which were covered with transparent  
533 films. Seven days after transplantation, the grafts were harvested. One part of each graft was  
534 paraffin-embedded and sectioned at 6  $\mu$ m, from which hematoxylin and eosin staining was prepared.  
535 Some sections were de-paraffinized and blocked for endogenous peroxidase activity, and then blood  
536 vessels were stained with rat antibody against CD31 (at 1:20 dilution, dianova GmbH, Hamburg,  
537 Germany), according to the manufacturer's instructions for the ImmPRESS<sup>TM</sup> reagent kit (Vector  
538 Laboratories, Burlingame, CA). The sections were counterstained with hematoxylin for cell nuclei.  
539 We performed at least three independent studies and confirmed similar results. A representative  
540 experiment is shown in the figures.

### 541 **Whole transcriptome analysis with RNA-seq**



542 Total RNA was extracted from the fibroblasts or LSE using the RNeasy Mini Kit (Qiagen, Hilden,  
543 Germany), and mRNA was purified with oligo dT beads (NEBNext Poly (A) mRNA magnet  
544 Isolation Module, New England Biolabs, NEB, Ipswich, MA). The procedure of the complementary  
545 DNA (cDNA) libraries was carried out with NEBNext Ultra II RNA library Prep kit (NEB) and  
546 NEBNextplex Oligos for Illumina following a previously described method (Kohno et al., 2020).  
547 Briefly, mRNA was incubated in NEBNext First Strand Synthesis Reaction Buffer at 94°C for 15  
548 min in the presence of NEBNext Random Primers, and reverse transcription was carried out with  
549 NEBNext Strand Synthesis Enzyme Mix. The index sequences were inserted to the fragments with  
550 PCR amplification. The libraries were added in equal molecular amounts and were sequenced on an  
551 Illumina Next-seq DNA sequencer with a 75-bp pair-end cycle sequencing kit (Illumina, San Diego,  
552 CA). The detected reads were analyzed using CLC Genomics Workbench software (ver.8.01,  
553 Qiagen). The pathway for the detected genes was analyzed using IPA (Qiagen).

#### 554 **Histology and immunohistochemical staining**

555 Paraffin-embedded LSE samples were sectioned at 6  $\mu\text{m}$  and stained with hematoxylin and eosin  
556 (H&E) or alcian blue (pH 2.5). For immunohistochemical staining, ImmPRESS<sup>TM</sup> reagent kit  
557 (Vector Laboratories) was used according to the manufacturer's instructions. Frozen sections (7  $\mu\text{m}$ )  
558 were first incubated with 0.3% hydrogen peroxide for 30 min to remove endogenous peroxidase  
559 activity and then incubated with primary antibodies at appropriate dilutions overnight at 4°C. The  
560 antibodies used in this study were n1584 for  $\alpha$ -SMA (Agilent technologies, Santa Clara, CA) and  
561 NCL-Ki67-MM1 for Ki67 (LeicaBiosystems, Buffalo Grove, IL). The sections were incubated with  
562 enzyme-conjugated secondary antibodies for 30 min at room temperature and then with the staining  
563 substrate. To determine if hyaluronan accumulates in LSEs, staining was carried out using  
564 biotinylated-hyaluronic acid-binding protein (Cosmo Bio). To detect elastic fibers in the tissue, EVG  
565 staining was performed using standard histological dyes for EVG staining (Muto Pure Chemicals,  
566 Tokyo, Japan). Images were obtained using Nikon ECLIPSE E600 microscope coupled with Nikon  
567 DS-R1 camera (Nikon, Tokyo, Japan).

#### 568 **Evaluating the epidermal spreading potential of trehalose-treated LSEs**

569 Rubber rings with an inner diameter of 8 mm were put on gels with or without trehalose in the gel  
570 (10, 30, and 100 mg/ml) and  $6 \times 10^5$  keratinocytes in 30  $\mu\text{l}$  MCDB 153 II medium were seeded into  
571 each ring hole. When the keratinocytes reached confluence, the LSEs were lifted to air-liquid  
572 surface, and the rubber rings were removed. At 14 days after airlifting, the epidermal size was

573 measured using computer-assisted morphometric analysis. The epidermal sizes of the conventional  
574 LSEs and trehalose-treated LSEs were compared statistically using Student's *t*-test.

#### 575 **SA- $\beta$ gal assay, p21 and dihydroethidium (DHE) immunocytochemistry**

576 SA- $\beta$ Gal assay was performed by seeding fibroblasts onto eight-well chamber slides and treating  
577 with trehalose or vehicle. Cells were also treated with adenovirus vectors that encode lacZ (Ax  
578 LacZ), following a previously described method (Tokumaru et al., 2005). Cells were fixed and  
579 stained with the Senescence Detection Kit (Cell Signaling Technology, Danvers, MA), following  
580 the manufacturer's instructions. The results were observed under a microscope. For p21  
581 immunocytochemistry, the treated fibroblasts were fixed with 4% paraformaldehyde/phosphate-  
582 buffered saline (PBS) for 30 min at room temperature, permeabilized with 0.5% Triton X-100/PBS  
583 for 15 min, incubated with antibodies raised against p21 #29475 (Cell Signaling Technology)  
584 overnight at 4°C after blocking with blocking solution (S3022, Dako) for 30 min, and then incubated  
585 with an Alexa Fluor 488-conjugated secondary antibody and DAPI (Thermo Fisher Scientific). The  
586 cells were mounted with VECTASHIELD (Vector Laboratories). Fluorescence was observed with  
587 a fluorescence microscope (Nikon) and analyzed by ImageJ (National Institutes of Health). For  
588 evaluating the superoxide production, the staining was done with DHE (ab145360, Abcam,  
589 Cambridge, UK) in dark and fluorescence images were taken using fluorescence microscope  
590 BZ9000 (Keyence, Osaka, Japan) with fluorescent filter OP-66838 (excitation 560/30 nm and  
591 emission 630/60 nm). Fluorescent signals were quantified using ImageJ (National Institutes of  
592 Health).

#### 593 **Cell death assays**

594 Cell viability was measured using a Cell Counting Kit-8 assay (Enzo life sciences, Farmingdale,  
595 NY) following the manufacturer's instructions. Optical density was measured at 450 nm and was  
596 normalized to the corresponding stimulation control.

#### 597 **Cell cycle analysis of monolayer fibroblasts and dermal cells in LSEs**

598 Single-cell preparations from the monolayer fibroblasts or the dermal side of LSE were carried out.  
599 The dermis was removed from the epidermis of the LSE cells. The dermis was further digested with  
600 collagenase XI and hyaluronidase (both from Sigma-Aldrich) for 120 min followed by fluorescence-  
601 activated cell sorting (FACS) analysis with propidium iodide (BioLegend, San Diego, CA)  
602 according to the propidium iodide cell cycle staining protocol.

#### 603 **RNA preparation and determination of mRNA expression by quantitative RT-PCR**



604 Total RNA was isolated by using the RNeasy Mini Kit (Qiagen), and real-time PCR was used to  
605 determine the mRNA abundance, as described previously (Dai et al., 2011). TaqMan™ Gene  
606 Expression Assays (Thermo Fisher Scientific) were used to analyze the expressions (Table S2).  
607 *GAPDH* mRNA was used as an internal control. Target gene mRNA expression was calculated  
608 relative to *GAPDH* mRNA, and all data are presented as normalized data compared to each control  
609 (mean of control cells or tissues).

### 610 **Small interfering RNA**

611 Silencer validated siRNA CDKN1A (AM51331, Thermo Fisher Scientific) was used for silencing  
612 CDKN1A, and the Silencer negative control siRNA (AM4611, Thermo Fisher Scientific) was used  
613 as control. Fibroblasts were transfected with siRNA using Lipofectamine RNAiMAX Transfection  
614 Reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. The cells were  
615 allowed to stabilize for 24 hours before trehalose or vehicle treatment.

### 616 **Western blotting analysis**

617 Following stimulation, total cell extracts were collected at the indicated times. To detect the protein  
618 levels, cell lysates were separated by SDS–polyacrylamide gel electrophoresis and transferred to  
619 polyvinylidene difluoride membranes. Analyses were performed using Amersham ECL Prime  
620 Western Blotting Detection Reagent (RPN2232) (GE Healthcare Life Sciences, Chicago, IL), and  
621 then the membranes were scanned using Image Quant LAS4010 (GE Healthcare Life Sciences). We  
622 obtained the primary antibodies for ERK (#9102), phospho-ERK (#4370), AKT (#9272), phospho-  
623 AKT (#9271), p21 waf/cipl (12p1) (#29475) (Cell Signaling Technology), LaminB (C-20) (catalog  
624 sc-6216) (Santa Cruz, Dallas, TX), DPT (AF4629) (R&D systems, Minneapolis, MN), and  $\beta$ -actin  
625 (#ab6276)(Abcam).

### 626 **DPT ELISA**

627 DPT in the cell culture supernatants were measured. A Human DPT ELISA Kit (Abcam) was used  
628 to measure DPT in LSE, according to the manufacturer's procedures.

### 629 **Statistics**

630 Statistical analysis was performed using a two-tailed Student's *t*-test, one- or two-way analysis of  
631 variance with Prism software (version 9; GraphPad Software, San Diego, CA). Results are expressed  
632 as the mean  $\pm$  standard deviation (SD). A *P*-value of  $<0.05$  was considered significant.

### 633 **Study approval**

634 All animal procedures performed in this study were reviewed and approved by the Ehime University  
635 Institutional Animal Care and Use Committee. The experiments were conducted in accordance with  
636 the NIH guidelines for care and use of animals and the recommendations of International  
637 Association for the Study of Pain.

638 **Acknowledgments:** This work was supported by TR SPRINT Stage-A Seeds (A209 and A054)  
639 from Japan Agency for Medical Research and Development (AMED). The authors would like to  
640 thank E. Tan and Dr. K. Kameda from Ehime University for performing the qPCR and flow  
641 cytometry experiments.

642 **Competing interests:** Authors declare that they have no competing interests.

643 **Data and materials availability:** All data are available in the paper or the supplementary materials.  
644 RNA sequence data are submitted to GEO under accession number GSE184892.

645 The following data sets were generated.

646 Jun Muto, Shinji Fukuda, Kenji Watanabe, Xiuju Dai, Teruko Tsuda, Takeshi Kiyoi, Hideki Mori,  
647 Ken Shiraishi, Masamoto Murakami, Shigeki Higashiyama, Yoichi Mizukami, Koji Sayama (2021)  
648 NCBI Gene Expression Omnibus ID GSE 184892.

649 Highly concentrated trehalose induces transient senescence-associated secretory phenotype in  
650 fibroblasts via CDKN1A/p21

651 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE184892>

652

653

654

655

656

657

658

659

660

661

662

663

664 **References**

- 665 Andriani F, Margulis A, Lin N, Griffey S, Garlick JA. Analysis of microenvironmental factors  
666 contributing to basement membrane assembly and normalized epidermal phenotype. *J Invest*  
667 *Dermatol* 2003;120(6):923-31.
- 668 Bartek J, Lukas J. Pathways governing G1/S transition and their response to DNA damage. *FEBS Lett*  
669 2001;490(3):117-22.
- 670 Basisty N, Kale A, Jeon OH, Kuehnemann C, Payne T, Rao C, et al. A proteomic atlas of senescence-  
671 associated secretomes for aging biomarker development. *PLoS Biol* 2020;18(1):e3000599.
- 672 Baus F, Gire V, Fisher D, Piette J, Dulic V. Permanent cell cycle exit in G2 phase after DNA damage in  
673 normal human fibroblasts. *EMBO J* 2003;22(15):3992-4002.
- 674 Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease:  
675 from mechanisms to therapy. *Nat Med* 2015;21(12):1424-35.
- 676 Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, et al. Placenta growth factor in  
677 diabetic wound healing: altered expression and therapeutic potential. *Am J Pathol*  
678 2006;169(4):1167-82.
- 679 Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark  
680 side of tumor suppression. *Annu Rev Pathol* 2010;5:99-118.
- 681 Courapied S, Cherier J, Vigneron A, Troadec MB, Giraud S, Valo I, et al. Regulation of the Aurora-A  
682 gene following topoisomerase I inhibition: implication of the Myc transcription factor. *Mol*  
683 *Cancer* 2010;9:205.
- 684 Da Silva-Alvarez S, Picallos-Rabina P, Antelo-Iglesias L, Triana-Martinez F, Barreiro-Iglesias A,  
685 Sanchez L, et al. The development of cell senescence. *Exp Gerontol* 2019;128:110742.
- 686 Dai X, Sayama K, Tohyama M, Shirakata Y, Hanakawa Y, Tokumaru S, et al. Mite allergen is a danger  
687 signal for the skin via activation of inflammasome in keratinocytes. *J Allergy Clin Immunol*  
688 2011;127(3):806-14 e1-4.
- 689 DeBosch BJ, Heitmeier MR, Mayer AL, Higgins CB, Crowley JR, Kraft TE, et al. Trehalose inhibits  
690 solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosis. *Sci Signal*  
691 2016;9(416):ra21.
- 692 Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, et al. An essential role for  
693 senescent cells in optimal wound healing through secretion of PDGF-AA. *Dev Cell*  
694 2014;31(6):722-33.
- 695 Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, et al. Aurora kinase A is a target  
696 of Wnt/beta-catenin involved in multiple myeloma disease progression. *Blood*

- 697 2009;114(13):2699-708.
- 698 Elbein AD. The metabolism of alpha, alpha-trehalose. *Adv Carbohydr Chem Biochem* 1974;30:227-56.
- 699 Failla CM, Odorisio T, Cianfarani F, Schietroma C, Puddu P, Zambruno G. Placenta growth factor is  
700 induced in human keratinocytes during wound healing. *J Invest Dermatol* 2000;115(3):388-95.
- 701 Fanale D, Bazan V, Corsini LR, Caruso S, Insalaco L, Castiglia M, et al. HIF-1 is involved in the negative  
702 regulation of AURKA expression in breast cancer cell lines under hypoxic conditions. *Breast*  
703 *Cancer Res Treat* 2013;140(3):505-17.
- 704 Fischer M, Quaas M, Steiner L, Engeland K. The p53-p21-DREAM-CDE/CHR pathway regulates G2/M  
705 cell cycle genes. *Nucleic Acids Res* 2016;44(1):164-74.
- 706 Freund A, Laberge RM, Demaria M, Campisi J. Lamin B1 loss is a senescence-associated biomarker.  
707 *Mol Biol Cell* 2012;23(11):2066-75.
- 708 Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1alpha is  
709 essential for cell cycle arrest during hypoxia. *Mol Cell Biol* 2003;23(1):359-69.
- 710 Herranz N, Gil J. Mechanisms and functions of cellular senescence. *J Clin Invest* 2018;128(4):1238-46.
- 711 Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between  
712 vessel regression and growth mediated by angiopoietins and VEGF. *Oncogene* 1999;18(38):5356-  
713 62.
- 714 Honda Y, Tanaka M, Honda S. Trehalose extends longevity in the nematode *Caenorhabditis elegans*.  
715 *Aging Cell* 2010;9(4):558-69.
- 716 Ishida Y, Kondo T, Kimura A, Matsushima K, Mukaida N. Absence of IL-1 receptor antagonist impaired  
717 wound healing along with aberrant NF-kappaB activation and a reciprocal suppression of TGF-  
718 beta signal pathway. *J Immunol* 2006;176(9):5598-606.
- 719 Ishida Y, Kuninaka Y, Nosaka M, Furuta M, Kimura A, Taruya A, et al. CCL2-Mediated Reversal of  
720 Impaired Skin Wound Healing in Diabetic Mice by Normalization of Neovascularization and  
721 Collagen Accumulation. *J Invest Dermatol* 2019;139(12):2517-27 e5.
- 722 Jun JI, Lau LF. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in  
723 cutaneous wound healing. *Nat Cell Biol* 2010;12(7):676-85.
- 724 Kim YY, Jee HJ, Um JH, Kim YM, Bae SS, Yun J. Cooperation between p21 and Akt is required for p53-  
725 dependent cellular senescence. *Aging Cell* 2017;16(5):1094-103.
- 726 Kirsner RS. The use of Apligraf in acute wounds. *J Dermatol* 1998;25(12):805-11.
- 727 Kohno M, Kobayashi S, Yamamoto T, Yoshitomi R, Kajii T, Fujii S, et al. Enhancing calmodulin binding  
728 to cardiac ryanodine receptor completely inhibits pressure-overload induced hypertrophic  
729 signaling. *Commun Biol* 2020;3(1):714.

- 730 Krishnaswamy VR, Korrapati PS. Role of dermatopontin in re-epithelialization: implications on  
731 keratinocyte migration and proliferation. *Sci Rep* 2014;4:7385.
- 732 Kurz DJ, Decary S, Hong Y, Erusalimsky JD. Senescence-associated (beta)-galactosidase reflects an  
733 increase in lysosomal mass during replicative ageing of human endothelial cells. *J Cell Sci*  
734 2000;113 ( Pt 20):3613-22.
- 735 Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice  
736 lacking a functional osteopontin gene (*spp1*). *J Clin Invest* 1998;101(7):1468-78.
- 737 Longo N, Bell GI, Shuster RC, Griffin LD, Langley SD, Elsas LJ. Human fibroblasts express the insulin-  
738 responsive glucose transporter (GLUT4). *Trans Assoc Am Physicians* 1990;103:202-13.
- 739 Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a  
740 natural antagonist for Tie2 that disrupts in vivo angiogenesis. *Science* 1997;277(5322):55-60.
- 741 Masuda F, Ishii M, Mori A, Uehara L, Yanagida M, Takeda K, et al. Glucose restriction induces transient  
742 G2 cell cycle arrest extending cellular chronological lifespan. *Sci Rep* 2016;6:19629.
- 743 Movafagh S, Crook S, Vo K. Regulation of hypoxia-inducible factor-1 $\alpha$  by reactive oxygen species: new  
744 developments in an old debate. *J Cell Biochem* 2015;116(5):696-703.
- 745 Musa J, Aynaud MM, Mirabeau O, Delattre O, Grunewald TG. MYBL2 (B-Myb): a central regulator of  
746 cell proliferation, cell survival and differentiation involved in tumorigenesis. *Cell Death Dis*  
747 2017;8(6):e2895.
- 748 O'Connor NE, Mullikena JB, Banks-Schlegel S, Kehinde O, Green H. Grafting of burns with cultured  
749 epithelium prepared from autologous epidermal cells. *Lancet* 1981;1(8211):75-8.
- 750 Ohtake S, Wang YJ. Trehalose: current use and future applications. *J Pharm Sci* 2011;100(6):2020-53.
- 751 Randall MJ, Jungel A, Rimann M, Wuertz-Kozak K. Advances in the Biofabrication of 3D Skin in vitro:  
752 Healthy and Pathological Models. *Front Bioeng Biotechnol* 2018;6:154.
- 753 Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation  
754 of keratinizing colonies from single cells. *Cell* 1975;6(3):331-43.
- 755 Shirakata Y. Regulation of epidermal keratinocytes by growth factors. *J Dermatol Sci* 2010;59(2):73-80.
- 756 Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, Hashimoto K. So-called biological dressing effects of  
757 cultured epidermal sheets are mediated by the production of EGF family, TGF- $\beta$  and VEGF.  
758 *J Dermatol Sci* 2003;32(3):209-15.
- 759 Shirakata Y, Ueno H, Hanakawa Y, Kameda K, Yamasaki K, Tokumaru S, et al. TGF- $\beta$  is not involved  
760 in early phase growth inhibition of keratinocytes by 1 $\alpha$ ,25(OH) $_2$ vitamin D $_3$ . *J Dermatol Sci*  
761 2004;36(1):41-50.
- 762 Singer MA, Lindquist S. Multiple effects of trehalose on protein folding in vitro and in vivo. *Mol Cell*

- 763 1998;1(5):639-48.
- 764 Song SB, Hwang ES. A Rise in ATP, ROS, and Mitochondrial Content upon Glucose Withdrawal  
765 Correlates with a Dysregulated Mitochondria Turnover Mediated by the Activation of the  
766 Protein Deacetylase SIRT1. *Cells* 2018;8(1).
- 767 Sun N, Ning B, Hansson KM, Bruce AC, Seaman SA, Zhang C, et al. Modified VEGF-A mRNA induces  
768 sustained multifaceted microvascular response and accelerates diabetic wound healing. *Sci Rep*  
769 2018;8(1):17509.
- 770 Takeuchi K, Nakazawa M, Ebina Y, Sato K, Metoki T, Miyagawa Y, et al. Inhibitory effects of trehalose  
771 on fibroblast proliferation and implications for ocular surgery. *Exp Eye Res* 2010;91(5):567-77.
- 772 Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, et al. Trehalose alleviates polyglutamine-  
773 mediated pathology in a mouse model of Huntington disease. *Nat Med* 2004;10(2):148-54.
- 774 Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y, et al. Induction of  
775 keratinocyte migration via transactivation of the epidermal growth factor receptor by the  
776 antimicrobial peptide LL-37. *J Immunol* 2005;175(7):4662-8.
- 777 Trakala M, Fernandez-Miranda G, Perez de Castro I, Heeschen C, Malumbres M. Aurora B prevents  
778 delayed DNA replication and premature mitotic exit by repressing p21(Cip1). *Cell Cycle*  
779 2013;12(7):1030-41.
- 780 Warfel NA, El-Deiry WS. p21WAF1 and tumorigenesis: 20 years after. *Curr Opin Oncol* 2013;25(1):52-  
781 8.
- 782 Whelan DS, Caplice NM, Clover AJP. Mesenchymal stromal cell derived CCL2 is required for  
783 accelerated wound healing. *Sci Rep* 2020;10(1):2642.
- 784 Wilkinson HN, Hardman MJ. Senescence in Wound Repair: Emerging Strategies to Target Chronic  
785 Healing Wounds. *Front Cell Dev Biol* 2020;8:773.
- 786 Wu CC, Yang TY, Yu CT, Phan L, Ivan C, Sood AK, et al. p53 negatively regulates Aurora A via both  
787 transcriptional and posttranslational regulation. *Cell Cycle* 2012;11(18):3433-42.
- 788 Wu DD, Feng C, Xu XY, Xiao JY, Liu C, Meng J, et al. Protein kinase B/Akt may regulate G2/M transition  
789 in the fertilized mouse egg by changing the localization of p21(Cip1/WAF1). *Cell Biochem Funct*  
790 2011;29(4):265-71.
- 791 Wu H, Chen H, Zheng Z, Li J, Ding J, Huang Z, et al. Trehalose promotes the survival of random-pattern  
792 skin flaps by TFEB mediated autophagy enhancement. *Cell Death Dis* 2019;10(7):483.
- 793 Yang L, Shirakata Y, Tamai K, Dai X, Hanakawa Y, Tokumaru S, et al. Microbubble-enhanced  
794 ultrasound for gene transfer into living skin equivalents. *J Dermatol Sci* 2005;40(2):105-14.
- 795 Yokomise H, Inui K, Wada H, Hasegawa S, Ohno N, Hitomi S. Reliable cryopreservation of trachea for

796           one month in a new trehalose solution. *J Thorac Cardiovasc Surg* 1995;110(2):382-5.  
797   Zhu H, Chang BD, Uchiumi T, Roninson IB. Identification of promoter elements responsible for  
798           transcriptional inhibition of polo-like kinase 1 and topoisomerase IIalpha genes by  
799           p21(WAF1/CIP1/SDI1). *Cell Cycle* 2002;1(1):59-66.

800

801

802

803

804


805

806

807

808





809

810 **Figure 1. Novel effect of trehalose in the preparation of living skin equivalents.** (A) Schematic  
 811 for the preparation of cultured skin equivalents. (B) Diameters of LSEs with or without  
 812 trehalose (100 mg/ml) added in the collagen gel, prepared in the Transwell-COL with 24-  
 813 mm insert in a six-well culture plate after 2-week airlifting at 37°C. Data are expressed as  
 814 means  $\pm$  SD for three LSEs, which are representative of three independent experiments with  
 815 similar results. \*\*\*\*:  $P < 0.0001$  versus vehicle control groups using Student *t*-test. (C)



816 Macroscopic pictures of LSEs with or without trehalose (10 and 100 mg/ml) added in the  
817 collagen gel after 2-week airlifting. **(D)** LSEs stained with hematoxylin and eosin (Scale bar  
818 = 50  $\mu\text{m}$ ). Paraffin-embedded sections of LSEs were sectioned and subjected to  
819 immunohistochemistry with Ki67 antibody (Scale bar = 100  $\mu\text{m}$ ). **(E)** Volcano plots showing  
820 gene expression in the absence or the presence of trehalose. Red or green rounds indicate  
821 genes that increased by more than 2-fold or decreased by less than the half, respectively,  
822 with less than 0.05 of q-values. **(F)** A principal component analysis (PCA) with gene  
823 expressions in the absence or the presence of trehalose showed no clear separation between  
824 principal component PC1 and PC2. **(G)** Schematic for the preparation of cultured skin  
825 equivalents with fibroblasts treated with or without trehalose before seeding in the dermal  
826 matrix. **(H)** Representative picture of LSEs with the fibroblast treated with or without  
827 trehalose (30 and 100 mg/ml) before seeding in the collagen gel after 1-week airlifting at  
828 37°C. Data are representative of three independent experiments.

829

830

831

832

833

834

835

836

837

838


839

840

841

842

843



845 **Figure 2. Highly concentrated trehalose-induced signaling pathways detected in human**  
846 **fibroblasts by whole transcriptome analysis with RNA-seq.** (A) The heatmap shows the  
847 z-scores of the gene expression downregulated in 2D and 3D fibroblasts by trehalose. (B)  
848 The Venn diagram demonstrates the numbers of downregulated genes. The 131 genes  
849 downregulated in 2D and 3D fibroblasts were used for an Ingenuity pathway analysis (IPA).  
850 (C) Canonical pathways detected in IPA using the genes downregulated by trehalose were  
851 shown together with number of genes involved in the detected pathway. (D) Upstream  
852 factors of the downregulated genes by trehalose were indicated together with the number of  
853 genes involved in the detected factor. The upstream factors signaling by activation or by  
854 inhibition were shown in brown or blue, respectively. (E) A network demonstrates the  
855 interaction of CDKN1A, which was detected as an upstream factor of the downregulated  
856 genes, and the signals inhibited by trehalose, which are shown as blue lines. The green shapes  
857 indicate the genes downregulated by trehalose. (F) A heatmap shows the z-scores of the gene  
858 expressions upregulated in 2D and 3D fibroblasts by trehalose. (G) The Venn diagram  
859 demonstrates the numbers of the upregulated genes. (H) Canonical pathways detected in IPA  
860 using the genes upregulated by trehalose were shown together with the number of genes  
861 involved in the detected pathway. (I) Upstream factors of the upregulated genes by trehalose  
862 were indicated together with the number of genes involved in the detected factors. The  
863 upstream factors signaling by activation or by inhibition were shown in brown or blue,  
864 respectively. (J) A network demonstrates the interaction of AURK, detected as an upstream  
865 factor of the downregulated genes, and the factors predicted to activate interaction with  
866 AURK by trehalose, which are shown as red lines. The red shapes indicate the genes  
867 upregulated by trehalose.

868

869

870


871

872

873

874

875



876

877 **Figure 3. Graphical summary and network analysis by IPA pathway using genes modulated**


878 **by trehalose. (A)** Venn diagram demonstrates the numbers of the downregulated genes

879 and the upregulated genes analyzed in Fig2. There were 131 downregulated genes and the

880 127 upregulated genes for an IPA. **(B)** A graphical summary shows the senescence cells,

881 which are induced by p53 and CDKN1A, connected by the network analysis to the cellular

882 functions.



883

884 **Figure 4. Trehalose modulates the expression of senescence and cell cycle arrest-related**  
 885 **molecules.** (A) Human dermal fibroblasts were treated with trehalose (30 and 100 mg/ml),  
 886 tetrasaccharide hyaluronan (HA oligo) (30 µg/ml), or vehicle (PBS) for 24 h. *CDKN1A* and  
 887 *LMNB1* mRNA expression were assessed by qPCR. Data are shown as relative expressions  
 888 to the control (vehicle-treated) fibroblasts. (B) Western blotting showing the expression of  
 889 p21, lamin B, and β-actin in human dermal fibroblasts treated with trehalose (30 mg/ml, 100  
 890 mg/ml) or the vehicle for 24 h. (C) Human dermal fibroblasts were treated with trehalose  
 891 (30 and 100 mg/ml) or vehicle control (PBS) for 24 h. The cells were stained with antibody

892 for p21 (green) and DAPI (blue) for nuclei and were observed using a fluorescence  
893 microscope. Scale bar = 100  $\mu$ m. (D) *AURKA*, *AURKB*, *AURKC*, *MYBL2*, *PLK1*, and  
894 *UBE2C* mRNA expressions were assessed by qPCR. Data are shown as the relative  
895 expression to the control (vehicle-treated) fibroblasts. (E) Trehalose (100 mg/ml) or vehicle  
896 (PBS) were added in the human dermal fibroblasts populated collagen gel for 72 h. *CDKN1A*,  
897 *LMNB1*, *AURKA*, *AURKB*, *UBE2C*, *PLK1*, and *MYBL2* mRNA expressions were assessed  
898 by qPCR. Data are shown as relative expression to the control (vehicle-treated). \*:  $P < 0.05$ ,  
899 \*\*:  $P < 0.01$ , \*\*\*:  $P < 0.001$ , \*\*\*\*:  $P < 0.0001$  versus the vehicle-treated control group by  
900 one-way ANOVA (A, D) or Student *t*-test (E). Data are expressed as means  $\pm$  SD for three  
901 wells (A, D) or three dermal substitutes (E), and are representative of three independent  
902 experiments.

903

904

905

906

907

908

909

910

911

912

913

914

915


916

917

918

919






920

921 **Figure 5. Trehalose arrests fibroblasts in the G2/M interphase of the cell cycle and triggers**  
922 **senescence with activation of Erk1/2 and Akt.** (A) Representative photos of human dermal  
923 fibroblasts treated with trehalose (10 and 100 mg/ml) or vehicle (PBS) for 24 h. Phase  
924 contrast micrographs, bar = 50 μm. (B) Fibroblasts were characterized for a potential  
925 senescent phenotype via SA-βGAL staining after treatment with trehalose (100 mg/ml),  
926 vehicle, or Ad-LacZ (MOI:30) for 24 h. Scale bar = 50 μm. (C) Western blotting showing  
927 the expression of ERK1/2, p-ERK1/2, AKT, p-AKT, and β-actin in human dermal fibroblasts  
928 treated with trehalose (10 and 100 mg/ml) or vehicle for 24 h. (D) Twenty-four hours after  
929 the trehalose (100 mg/ml) or vehicle treatment, human dermal fibroblasts were stained with  
930 propidium iodide, and the percentage of G2/M cells was measured by flow cytometry.  
931 Representative FACS images. (E) Seven days after air exposure, human dermal fibroblasts  
932 in the living skin equivalent were stained with propidium iodide, and the percentage of G2/M  
933 cells was measured by flow cytometry. Representative FACS images. Data are  
934 representative of two independent experiments.

935





937 **Figure 6. Trehalose induces an increase in the expression of wound healing-related molecules.**

938 (A) Human dermal fibroblasts were treated with trehalose (30 and 100 mg/ml),  
939 tetrasaccharide hyaluronan (HA oligo) (30 µg/ml), or vehicle control (PBS) for 24 h. *EREG*,  
940 *ARG2*, *CCL2*, *IL-1RN*, *PGF*, *SPPI*, *VEGF*, *ANGPT2*, and *DPT* mRNA expressions were  
941 assessed by qPCR. Data are shown as relative expression to the control (0 h) fibroblasts. For  
942 *FGF2* mRNA expression, data are shown as relative expression to vehicle control groups at  
943 24 hours. (B) DPT was measured by ELISA in the culture medium of human dermal  
944 fibroblasts. One set of fibroblasts was treated with trehalose 30 or 100 mg/ml, tetrasaccharide  
945 hyaluronan (HA) (30 µg/ml), or the vehicle (PBS) for 24 or 48 h ( $n = 3$ ). (C) Representative  
946 Western blots showing DPT and  $\beta$ -actin expression in human dermal fibroblasts 24 or 48 h  
947 after vehicle, trehalose 30 or 100 mg/ml, tetrasaccharide hyaluronan (HA) (30 µg/ml)  
948 exposure. (D) Trehalose (100 mg/ml) or vehicle were added in the human dermal fibroblasts  
949 populated collagen gel for 72 h. *DPT*, *EREG*, *VEGF*, *FGF2*, *ANGPT2*, *ARG2*, *CCL2*, *IL-*  
950 *1RN*, *PGF*, and *SPPI* mRNA expression were assessed by qPCR. Data are shown as the  
951 relative expression to the control (vehicle-treated). \*:  $P < 0.05$ , \*\*:  $P < 0.01$ , \*\*\*:  $P < 0.001$ ,  
952 \*\*\*\*:  $P < 0.0001$  versus the vehicle-treated control group by one-way ANOVA (A, B) or  
953 Student *t*-test (D). Data are expressed as means  $\pm$  SD for three wells (A, D) or three dermal  
954 substitutes (D), and representative of three independent experiments.

955

956

957

958

959

960


961

962

963

964

965




966

967 **Figure 7. CDKN1A is involved in trehalose-induced increase in the mRNA expression of**  
968 **wound healing-related molecules. (A)** After transfection with control or *CDKN1A* siRNA,  
969 human dermal fibroblasts were treated with trehalose (100 mg/ml) or vehicle control (PBS)  
970 for 48 h. *CDKN1A*, *DPT*, *ANGPT2*, *VEGF*, *EREG*, and *FGF2* mRNA expressions were  
971 assessed by qPCR. Data are shown as relative expression to the control siRNA and vehicle  
972 treated fibroblasts. Data are expressed as means  $\pm$  SD, and representative of two independent  
973 experiments with similar results. \*:  $P < 0.05$ , \*\*:  $P < 0.01$ , \*\*\*\*:  $P < 0.0001$  versus the  
974 relevant control group, and #:  $P < 0.01$ , ###:  $P < 0.001$ , #####:  $P < 0.0001$  versus the control  
975 siRNA-treated group of vehicle treated fibroblasts by two-way ANOVA.

976

977

978



979

980 **Figure 8. Graft of dermal substitute with highly concentrated trehalose-treated fibroblasts on**  
981 **nude mice accelerates murine wound closure and angiogenesis.** (A) Representative  
982 photographs of the wound area on the recipient nude mice as indicated at 7 days after  
983 transplantation. (B) Wound closure was quantified and presented as % wound closure; % =  
984 the percentage of the initial wound area size at day 7 when comparing the trehalose-LSE  
985 group (red band) to the control group (blue band). (C) Representative photographs of  
986 angiogenesis induced by the grafts. (D) Images of the H&E-stained tissue sections from the

987 wound sites at day 7. Bars = 1 mm. (E) Quantitative analysis of gap of the wounds in  
988 comparison between the trehalose-LSE group (red band) and control group (blue band). (F)  
989 Images of CD31 immunostaining on the day 7 wounds. Bars = 50  $\mu$ m (G) Quantitative  
990 analysis of CD31 positive vessels per field. Data are expressed as means  $\pm$  SD. A subsequent  
991 statistical analysis was performed with Student *t*-test. \*:  $P < 0.05$ , \*\*:  $P < 0.01$ , with four  
992 mice in the control group, five in the trehalose-LSE group, and one tissue section from each  
993 mouse. Data are representative of three independent experiments.

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008


1009

1010

1011

1012

1013



1014

1015 **Figure 9. Graphical abstract: Novel trehalose-induced transient SASP accelerates organotypic**  
1016 **skin culture generation and facilitates cutaneous wound closure.**

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

## **Supplemental Information**

### **Highly concentrated trehalose induces transient senescence-associated secretory phenotype in fibroblasts via CDKN1A/p21**


1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053

Jun Muto<sup>1\*</sup>, Shinji Fukuda<sup>2</sup>, Kenji Watanabe<sup>3</sup>, Xiuju Dai<sup>1</sup>, Teruko Tsuda<sup>1</sup>, Takeshi Kiyoi<sup>4</sup>, Hideki Mori<sup>1</sup>, Ken Shiraishi<sup>1</sup>, Masamoto Murakami<sup>1</sup>, Shigeki Higashiyama<sup>5, 6</sup>, Yoichi Mizukami<sup>3</sup>, Koji Sayama<sup>1</sup>

#### **Affiliations:**

<sup>1</sup>Department of Dermatology, Ehime University Graduate School of Medicine; Toon, Japan.  
<sup>2</sup>Department of Biochemistry, School of Dentistry, Aichi Gakuin University; Nagoya, Japan.  
<sup>3</sup>Institute of Gene Research, Yamaguchi University Science Research Center; Yamaguchi, Japan.  
<sup>4</sup>Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Japan.  
<sup>5</sup>Division of Cell Growth and Tumor Regulation, Proteo-Science Center, Ehime University; Toon, Japan.  
<sup>6</sup>Department of Molecular and Cellular Biology, Osaka International Cancer Institute; Osaka, Japan.

\*Corresponding author. Email: [junmuto@m.ehime-u.ac.jp](mailto:junmuto@m.ehime-u.ac.jp)




1054

1055 **Figure 1-figure supplement 1: Novel effect of highly concentrated trehalose in the preparation**  
1056 **of living skin equivalents.** (A) A schematic for the preparation of cultured skin equivalents. (B)  
1057 Macroscopic pictures of LSEs with and without trehalose (30 and 100 mg/ml) added in the collagen  
1058 gel. The gel was prepared in the Transwell-COL with 24-mm insert in a six-well culture plate after  
1059 1-week of airlifting at 37°C. (C) Diameters of LSEs with and without trehalose added in the collagen  
1060 gel after 1-week of airlifting at 37°C. Data are expressed as means  $\pm$  SD for three LSEs. \*\*\*\*:  $P <$   
1061 0.0001 versus vehicle control groups in Student  $t$ -test.

1062

1063






1064

1065 **Figure 1-figure supplement 2: Immunostaining of living skin equivalents prepared with or**  
1066 **without trehalose (10 and 100 mg/ml).** Paraffin-embedded sections of LSEs were sectioned and  
1067 subjected to immunohistochemistry for Elastica van Gieson staining (A), hyaluronan-binding  
1068 protein (HABP) staining (B), Alcian blue staining, PH 2.5 (C),  $\alpha$ -SMA staining (D). Scale bar = 80  
1069  $\mu\text{m}$ .

1070



1071

1072 **Figure 1-figure supplement 3: Novel effect of trehalose in the preparation of living skin**  
1073 **equivalents.** Representative picture of LSEs with or without trehalose (100 mg/ml) added in the  
1074 collagen gel, which was prepared in a 100-mm dish after 2-weeks of airlifting at 37°C. Data are  
1075 representative of two independent experiments.

1076

1077

1078

1079

1080


1081

1082

1083

1084

1085



1086

1087

1088

1089

1090

1091

1092

1093


1094

1095

1096

1097

**Figure 2-figure supplement 1: Gene expressions in highly concentrated trehalose-treated 2D and 3D fibroblasts by whole transcriptome analysis with RNA-seq.** Volcano plots show that in the presence of trehalose (100 mg/ml) in 2D fibroblasts (**A**) and 3D fibroblasts (**D**), gene expressions were significantly modulated. Red or green rounds indicate genes increased more than 2-fold or decreased by less than the half, respectively, with less than 0.05 of q-values. PCA showing the separation between PC1 and PC2 in 2D fibroblasts (**B**) and 3D fibroblasts (**E**). The factor loadings of PC1 and PC2 of the genes calculated by PCA were plotted. The plotted upper and lower genes were detected in 2D fibroblasts (**C**) or 3D fibroblasts (**F**).




1098

1099

1100 **Figure 3-figure supplement 1: Network analysis by IPA pathway using genes modulated by**  
 1101 **trehalose.** (A) The Venn diagram demonstrates the numbers of the downregulated genes and the  
 1102 upregulated-genes analyzed in Fig. 2. The 131 downregulated-genes and the 127 upregulated-  
 1103 genes were used for an IPA. (B) A network detected by IPA demonstrated activation of DPT and  
 1104 Vegf, accompanied by inhibition of PLK1, LMNB1, and CDK1. The red and green shapes  
 1105 demonstrate upregulated and downregulated genes by trehalose, respectively.

1106

1107



1108

1109 **Figure 4-figure supplement 1: Trehalose modulates the expression of p21.** Human dermal  
1110 fibroblasts were treated with trehalose (30 and 100 mg/ml) or a vehicle control (PBS) for 24 hours.  
1111 The cells were stained with antibody for p21 and DAPI for nuclei, and both were observed using a  
1112 fluorescence microscope. In each group, we observed the relative number and intensity of fibroblasts  
1113 stained by p21 antibody. Data are means  $\pm$  SD for four wells, and are representative of three  
1114 experiments with similar results. \*\*\*:  $P < 0.001$ , \*\*\*\*:  $P < 0.0001$  versus the control (vehicle-  
1115 treated) fibroblasts by one-way ANOVA).

1116

1117

1118

1119

1120

1121

1122


1123

1124

1125

1126





1127

1128 **Figure 5-figure supplement 1: Proliferation assay with human dermal fibroblasts treated with**  
1129 **trehalose.** Proliferation assay with human dermal fibroblasts treated with trehalose (10, 30, and 100  
1130 mg/ml) or vehicle for 24 h.

1131

1132

1133

1134


1135

1136

1137

1138





1139

1140 **Figure 5-figure supplement 2: Fluorescent images of trehalose-treated fibroblasts stained with**  
1141 **DHE.** (A) Fibroblasts were treated with vehicle or trehalose (100 mg/ml) for 48 hours and stained  
1142 with DAPI for nuclei. Representative fluorescent images of DHE-treated cells were obtained by  
1143 fluorescence microscope. (B) In each group, we observed the intensity per cell stained with DHE.  
1144 Data are means  $\pm$  SD for four wells and are representative of two experiments with similar results.  
1145 \*\*:  $P < 0.001$  versus the control (vehicle-treated) fibroblasts by Student *t*-test.

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

Gene Symbol	2D Fibroblast			3D Fibroblast		
	Log <sub>2</sub> Fold Change	P value	q value	Log <sub>2</sub> Fold Change	P value	q value
CCL26	15.6887127	2.0027E-05	0.00044792	1.705299024	0.000739	0.008949
CCL5	1.068414138	0.45589618	0.45288915	-0.173989996	0.327876	0.492259
CTSB	0.971606011	0.06904278	0.1363981	0.335018077	0.000016	0.001276
CXCL1	1.068140074	0.73874177	0.65627578	-0.874653559	0.002441	0.019497
CXCL5	0.94567579	0.75128719	0.66503826	-0.777055659	0.001055	0.011256
IL1B	1.038811561	0.37390097	0.38579554	-0.000435529	0.998081	0.929793
IL8	0.749017012	0.40241364	0.4091766	-1.863078226	0.000022	0.001431
IL6	1.83106492	0.03268861	0.07368166	0.560710784	0.01188	0.058068
IL6ST	0.768246043	0.00028053	0.00211584	-0.153220532	0.008595	0.046269
IL6R	0.961693449	0.60541119	0.56747153	0.340425901	0.022357	0.091428
IL11	1.38408421	0.00127207	0.00602665	-0.641457641	0.000063	0.002266
GDF15	5.504128467	5.3168E-06	0.00021386	2.204582142	0.000023	0.001467
ICAM3	1.10713058	0.17158772	0.26835683	-0.04654121	0.784125	0.816121
IGFBP2	0.816306772	0.21727315	0.32304459	0.153371435	0.499837	0.607437
IGFBP4	0.676750709	1.1438E-05	0.0003231	-0.096631441	0.019633	0.083265
IGFBP6	0.599951743	2.1271E-05	0.0004627	-0.440933601	0.000426	0.006395
INHBA	0.919449668	0.27440813	0.38579554	0.282262443	0.002374	0.019129
KITLG	1.193926054	0.00022606	0.00185082	0.153844064	0.005932	0.035706
LIF	0.733713608	0.00408197	0.01444751	0.198355932	0.053675	0.173018
MMP1	1.107060554	0.00487661	0.01651	0.917704713	0.000062	0.00226
MMP3	1.286485945	3.9542E-05	0.00063832	2.32521748	<0.000001	0.000541
MMP10	1.466808305	0.00679295	0.02126738	1.567801079	0.000048	0.002069
MMP12	1.614463727	0.01064761	0.03018434	0.47100454	0.058762	0.185098
MMP14	0.555567434	7.3144E-06	0.00025431	0.129684845	0.003357	0.024065
PLAT	2.985791621	9.1255E-06	0.00028893	-0.25587261	0.025534	0.100313
PLAU	0.699589106	2.2605E-05	0.0004765	-0.085737884	0.136164	0.323803
PLAUR	0.804912306	0.00707554	0.02193321	-0.448530887	0.000271	0.004945
SERPINB2	0.935304804	0.55097058	0.52692515	-0.108924632	0.364082	0.492259
TIMP1	0.899312334	0.00046492	0.00295382	-0.13252159	0.01695	0.07489
TNFRSF10C	4.022071381	6.6203E-05	0.00085594	2.191704997	0.000001	0.000567
STC1	0.872968807	0.08588855	0.16310923	0.268688045	0.008082	0.044319
HMGB1	0.749005876	3.46E-05	0.00059345	-0.672302379	0.000018	0.001331
CALR	0.844018275	3.6457E-06	0.00017579	-0.358529449	0.000113	0.003023
CD44	0.506002712	1.0211E-07	5.1976E-05	-0.126432638	0.020103	0.084665
S100A11	1.039862234	0.11871843	0.20483225	0.06647586	0.10953	0.293671
LGALS3BP	0.807693816	0.00822613	0.02470954	-0.307984476	0.016317	0.07301
VCAN	0.720397578	0.00094683	0.00486125	-0.47473911	0.000133	0.003325
TNC	3.665322378	1.0098E-07	5.1976E-05	-0.100713946	0.023494	0.094632
HSPA5	0.749125475	7.657E-06	0.00025961	-0.618822695	0.000002	0.000603
HSP90AB1	0.748200289	2.7946E-06	0.00015423	-0.10722718	0.012148	0.059095
HSPA8	1.358284902	1.1828E-05	0.00032903	0.014429089	0.628248	0.707638
HSPA1A	2.360615298	1.9545E-06	0.00012892	-0.659152755	0.007447	0.041969
HSP90AA1	1.105287269	0.00070951	0.0039587	-0.063762606	0.018879	0.081054
HSP90B1	0.645522626	7.4136E-07	0.00010197	-0.874711901	0.000005	0.000797

1157

1158 **Table 1. Expression of SASP factor genes by highly concentrated trehalose.** Analysis of RNA-  
 1159 seq data revealed that several genes associated with trehalose-induced premature senescence were  
 1160 upregulated.

1161

1162

1163

1164

1165

1166

Gene symbol	Assay ID	Gene Name
EREG	Hs00914313_m1	Epiregulin
AREG	Hs00950669_m1	Amphiregulin
GAPDH	Hs02758991_g1	Glyceraldehyde-3-Phosphate Dehydrogenase
ARG2	Hs00982833_m1	Arginase 2
PGF	Hs00182176_m1	Placental Growth Factor
VEGFA	Hs00900055_m1	Vascular Endothelial Growth Factor A
DPT	Hs00355056_m1	Dermapontin
CCL2	Hs00234140_m1	C-C Motif Chemokine Ligand 2
SPP1	Hs00959010_m1	Secreted Phosphoprotein 1
IL1RN	Hs00893626_m1	Interleukin 1 Receptor Antagonist
ANGPT2	Hs00169867_m1	Angiopoietin 2
AURKA	Hs00269212_m1	Aurora Kinase A
AURKB	Hs00177782_m1	Aurora Kinase B
AURKC	Hs00152930_m1	Aurora Kinase C
CDKN1A	Hs00355782_m1	Cyclin Dependent Kinase Inhibitor 1A
PLK1	Hs00983227_m1	Polo Like Kinase 1
LMNB1	Hs01059210_m1	Lamin B1
FGF2	Hs00960934_m1	Fibroblast Growth Factor 2
MYBL2	Hs00942540_m1	MYB Proto-Oncogene Like 2
UBE2C	Hs00153153_m1	Ubiquitin Conjugating Enzyme E2 C
HIF1A	Hs00152153_m1	Hypoxia Inducible Factor 1 Subunit Alpha

1167

1168

1169

1170 **Table 2. TaqMan primers and probe assay ID (Applied Biosystems) of the genes used in real-**  
 1171 **time PCR.**

1172

1173

1174

1175

1176

1177

1178

1179

1180 **Video 1.** The morphological alterations of the human dermal fibroblasts after vehicle treatment.  
1181 Phase contrast microscopy imaging of the fibroblasts cultured with vehicle.

1182 **Video 2.** The morphological alterations of the human dermal fibroblasts after the trehalose treatment  
1183 (30 mg/ml). Phase contrast microscopy imaging of the fibroblasts cultured with trehalose.

1184 **Video 3.** The morphological alterations of the human dermal fibroblasts after the trehalose treatment  
1185 (100 mg/ml). Phase contrast microscopy imaging of the fibroblasts cultured with trehalose.

1186 **Video 4.** The morphological alterations of the human dermal fibroblasts after the sucrose treatment  
1187 (100 mg/ml). Phase contrast microscopy imaging of the fibroblasts cultured with sucrose.

1188

1189

1190

1191